




1/27

Resistance Test Vector



Resistance Test Vector




Fig. 1



Two Cell Assay





Fig. 2




3/27

Drug Resistance: NRTI, NNRTI, PI

AZT



DEL



RTV




Fig. 3



4/27

Drug Susceptibility Test Profile: Patient 487




Fig. 4A



Drug Susceptibility Test Profile: Patient 487




Fig. 4B



6/27

Drug Susceptibility Test Profile: Patient 487





Fig. 4C



7/27

Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 5



8/27

Drug Susceptibility Test Profile: Patient 268





Fig. 6A



9/27

Drug Susceptibility Test Profile: Patient 268




Fig. 6B



10/27

Drug Susceptibility Test Profile: Patient 268





Fig. 6C



11/27

Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 7A



12/27

Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 7B



Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 7C

Drug Susceptibility Test Profile: Patient 302







Fig. 8A



15/27

Drug Susceptibility Test Profile: Patient 302




Fig. 8B



16/27

Drug Susceptibility Test Profile: Patient 302




Fig. 8C



17/27

Drug Susceptibility Test Profile: Patient 780







Fig. 8D

Drug Susceptibility Test Profile: Patient 780




Fig. 8E

DEC 17 2003

PATENTS & TRADEMARK OFFICE
U.S. GOVERNMENT

19/27

Drug Susceptibility Test Profile: Patient 780





Fig. 8F



20/27

Drug Susceptibility Test Profile: Patient 302 Virus Clones





Fig. 8G



Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 8H



22/27

Drug Susceptibility Test Profile: Site Directed Mutants




Fig. 8I



Drug Susceptibility Test Profile: Site Directed Mutants






Fig. 8] 

DEC 17 2003

PATENT & TRADEMARK OFFICE
U.S. GOVERNMENT

24/27

Drug Susceptibility Test Profile: Patient 644




Fig. 9A



Drug Susceptibility Test Profile: Patient 644






Fig. 9B



Drug Susceptibility Test Profile: Patient 644



26/27




Fig. 9C




Fig. 9D